Erste Asset Management GmbH Buys New Shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Erste Asset Management GmbH purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 41,363 shares of the medical equipment provider’s stock, valued at approximately $4,476,000.

Several other large investors have also recently added to or reduced their stakes in ZBH. Ashton Thomas Securities LLC acquired a new position in shares of Zimmer Biomet in the third quarter valued at $28,000. Bangor Savings Bank bought a new stake in Zimmer Biomet in the 3rd quarter valued at $31,000. Family Firm Inc. acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at $33,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the 3rd quarter worth about $35,000. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Zimmer Biomet during the 2nd quarter valued at about $43,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of NYSE:ZBH opened at $110.50 on Tuesday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The stock has a market capitalization of $22.00 billion, a P/E ratio of 21.01, a P/E/G ratio of 2.06 and a beta of 1.02. The business has a 50-day moving average price of $107.29 and a two-hundred day moving average price of $109.30.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. Zimmer Biomet’s revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.65 earnings per share. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ZBH. Truist Financial increased their price target on shares of Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a research report on Friday, November 1st. JPMorgan Chase & Co. dropped their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating for the company in a report on Monday, September 16th. BTIG Research lowered their price target on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research report on Thursday, October 3rd. Oppenheimer cut their price objective on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Finally, Royal Bank of Canada upped their target price on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $123.22.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.